Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice.
The methods exploit a feature of Oxford Nanopore's technology that ejects molecules mid-read, enabling a new level of control over human DNA sequencing runs.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
In addition to developing standards for proteomics, metabolomics, and other kinds of data, DNAnexus will develop tools to help reviewers quickly and easily assess analysis pipelines.
The company uses systems biology approaches and AI methods to model and analyze causal pathways in diseases including neurological cancers and Alzheimers.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
